30 May 2025 - Ipsen Korea’s months-long effort to expand reimbursement for Cabometyx (cabozantinib) has ended in failure, cutting off what could have been a crucial second-line treatment option for kidney cancer patients whose disease progresses after immunotherapy.

The collapse, confirmed Monday after the May deadline for price negotiations passed, cuts off a treatment path that had gained regulatory support earlier this year -- and forces Ipsen back to square one if it wants to try again.

Read Korea Biomedical Review article